Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT2 receptor?

European Journal of Pharmacology

Volumn 588, Issue 2-3, 2008, Pages 286-293

  van Esch, Joep H M ^a   Oosterveer, Chantal R ^a   Batenburg, Wendy W ^a   van Veghel, Richard ^a   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin; Angiotensin AT2 receptor; Angiotensin AT4 receptor; Mas receptor; Metabolite

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; IRBESARTAN;

ABDOMINAL AORTA; AGONIST; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DRUG RECEPTOR BINDING; ILIAC ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY;

ANGIOTENSIN II; ANGIOTENSIN III; ANIMALS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LIGANDS; MALE; NG-NITROARGININE METHYL ESTER; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; VASOCONSTRICTION;

EID: 44649165636     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.042     Document Type: Article

References (52)

1. AbdAlla S., Lother H., Abdel-tawab A.M., and Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. 276 (2001) 39721-39726
2. Abdellatif M.M., Neubauer C.F., Lederer W.J., and Rogers T.B. Angiotensin-induced desensitization of the phosphoinositide pathway in cardiac cells occurs at the level of the receptor. Circ. Res. 69 (1991) 800-809
3. Ardaillou R., and Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int. 52 (1997) 1458-1468
4. Batenburg W.W., Garrelds I.M., Bernasconi C.C., Juillerat-Jeanneret L., van Kats J.P., Saxena P.R., and Danser A.H.J. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109 (2004) 2296-2301
5. Campbell D.J., and Kladis A. Simultaneous radioimmunoassay of six angiotensin peptides in arterial and venous plasma of man. J. Hypertens. 8 (1990) 165-172
6. Campbell D.J., Lawrence A.C., Towrie A., Kladis A., and Valentijn A.J. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18 (1991) 763-773
7. Campbell D.J., Kladis A., and Duncan A.M. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 22 (1993) 513-522
8. Cazaubon C., Gougat J., Bousquet F., Guiraudou P., Gayraud R., Lacour C., Roccon A., Galindo G., Barthelemy G., Gautret B., et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265 (1993) 826-834
9. Chai W., Garrelds I.M., Arulmani U., Schoemaker R.G., Lamers J.M., and Danser A.H.J. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. Br. J. Pharmacol. 145 (2005) 664-671
10. Danser A.H.J., Koning M.M., Admiraal P.J.J., Derkx F.H.M., Verdouw P.D., and Schalekamp M.A.D.H. Metabolism of angiotensin I by different tissues in the intact animal. Am. J. Physiol. 263 (1992) H418-H428
11. Danser A.H.J., Koning M.M., Admiraal P.J.J., Sassen L.M.A., Derkx F.H.M., Verdouw P.D., and Schalekamp M.A.D.H. Production of angiotensins I and II at tissue sites in intact pigs. Am. J. Physiol. 263 (1992) H429-H437
12. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
13. DeLean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-E102
14. Feng Y.H., Noda K., Saad Y., Liu X.P., Husain A., and Karnik S.S. The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. J. Biol. Chem. 270 (1995) 12846-12850
15. Ferreira A.J., Jacoby B.A., Araujo C.A., Macedo F.A., Silva G.A., Almeida A.P., Caliari M.V., and Santos R.A. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am. J. Physiol, Heart Circ. Physiol. 292 (2007) H1113-H1119
16. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., and Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377 (1995) 744-747
17. Ichiki T., Labosky P.A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B.L., and Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377 (1995) 748-750
18. Iglesias A.G., Suarez C., Feierstein C., Diaz-Torga G., and Becu-Villalobos D. Desensitization of angiotensin II: effect on [Ca2+]i, inositol triphosphate, and prolactin in pituitary cells. Am. J. Physiol., Endocrinol Metabol. 280 (2001) E462-E470
19. Le M.T., Vanderheyden P.M., Szaszak M., Hunyady L., and Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. J. Biol. Chem. 277 (2002) 23107-23110
20. Li Q., Zhang L., Pfaffendorf M., and van Zwieten P.A. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br. J. Pharmacol. 116 (1995) 2963-2970
21. Li Q., Feenstra M., Pfaffendorf M., Eijsman L., and van Zwieten P.A. Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein. J. Cardiovasc. Pharmacol. 29 (1997) 451-456
22. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., and van Gilst W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
23. MaassenVanDenBrink A., de Vries R., Saxena P.R., Schalekamp M.A.D.H., and Danser A.H.J. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc. Res. 44 (1999) 407-415
24. Macari D., Bottari S., Whitebread S., De Gasparo M., and Levens N. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. Eur. J. Pharmacol. 249 (1993) 85-93
25. Mulvany M.J., and Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41 (1977) 19-26
26. Munzenmaier D.H., and Greene A.S. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 27 (1996) 760-765
27. Noda K., Feng Y.H., Liu X.P., Saad Y., Husain A., and Karnik S.S. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 (1996) 16435-16442
28. Nouet S., and Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol. Metab. 11 (2000) 1-6
29. Padia S.H., Howell N.L., Siragy H.M., and Carey R.M. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 47 (2006) 537-544
30. Padia S.H., Kemp B.A., Howell N.L., Siragy H.M., Fournie-Zaluski M.C., Roques B.P., and Carey R.M. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 49 (2007) 625-630
31. Patel J.M., Martens J.R., Li Y.D., Gelband C.H., Raizada M.K., and Block E.R. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am. J. Physiol. 275 (1998) L1061-L1068
32. Reagan L.P., Ye X., Maretzski C.H., and Fluharty S.J. Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells. J. Neurochem. 60 (1993) 24-31
33. Robertson M.J., Cunoosamy M.P., and Clark K.L. Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta. Br. J. Pharmacol. 106 (1992) 166-172
34. Santos R.A.S., Campagnole-Santos M.J., and Andrade S.P. Angiotensin-(1-7): an update. Regul. Pept. 91 (2000) 45-62
35. Santos R.A.S., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8258-8263
36. Santos R.A.S., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., Cruz J.S., Ramos A.S., Rosa K.T., Irigoyen M.C., Bader M., Alenina N., Kitten G.T., and Ferreira A.J. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47 (2006) 996-1002
37. Schindler C., Bramlage P., Kirch W., and Ferrario C.M. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc. Health Risk Manag. 3 (2007) 125-137
38. Schuijt M.P., Basdew M., van Veghel R., de Vries R., Saxena P.R., Schoemaker R.G., and Danser A.H.J. AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction. Am. J. Physiol, Heart Circ. Physiol. 281 (2001) H2590-H2596
39. Schuijt M.P., Tom B., de Vries R., Saxena P.R., Sluiter W., van Kats J.P., and Danser A.H.J. Superoxide does not mediate the acute vasoconstrictor effects of angiotensin II: a study in human and porcine arteries. J. Hypertens. 21 (2003) 2335-2344
40. Shibasaki Y., Mori Y., Tsutumi Y., Masaki H., Sakamoto K., Murasawa S., Maruyama K., Moriguchi Y., Tanaka Y., Iwasaka T., Inada M., and Matsubara H. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin. Nephrol. 51 (1999) 83-91
41. Stegbauer J., Vonend O., Oberhauser V., and Rump L.C. Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J. Hypertens. 21 (2003) 1391-1399
42. Swanson G.N., Hanesworth J.M., Sardinia M.F., Coleman J.K., Wright J.W., Hall K.L., Miller-Wing A.V., Stobb J.W., Cook V.I., Harding E.C., et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 40 (1992) 409-419
43. Tom B., de Vries R., Saxena P.R., and Danser A.H.J. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38 (2001) 95-99
44. Ueda S., Masumori-Maemoto S., Ashino K., Nagahara T., Gotoh E., Umemura S., and Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35 (2000) 998-1001
45. van der Wouden E.A., Ochodnicky P., van Dokkum R.P., Roks A.J., Deelman L.E., de Zeeuw D., and Henning R.H. The role of angiotensin(1-7) in renal vasculature of the rat. J. Hypertens. 24 (2006) 1971-1978
46. van Esch J.H.M., Schuijt M.P., Sayed J., Choudhry Y., Walther T., and Danser A.H.J. AT(2) receptor-mediated vasodilation in the mouse heart depends on AT(1A) receptor activation. Br. J. Pharmacol. 148 (2006) 452-458
47. van Kesteren C.A.M., van Heugten H.A.A., Lamers J.M.J., Saxena P.R., Schalekamp M.A.D.H., and Danser A.H.J. Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J. Mol. Cell. Cardiol. 29 (1997) 2147-2157
48. van Rodijnen W.F., van Lambalgen T.A., van Wijhe M.H., Tangelder G.J., and Ter Wee P.M. Renal microvascular actions of angiotensin II fragments. Am. J. Physiol., Renal Physiol. 283 (2002) F86-F92
49. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., and Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277 (2002) 14838-14843
50. Vinh A., Widdop R.E., Drummond G.R., and Gaspari T.A. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc. Res. 77 (2008) 178-187
51. Widdop R.E., Walters P.E., and Gaspari T.A. Are angiotensin peptide fragments endogenous ligands for the AT2 receptor?. J. Hypertens. 24 Suppl 6 (2006) S186
52. Wright J.W., and Harding J.W. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul. Pept. 59 (1995) 269-295